|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 乳腺癌发生模型MCF10各细胞系中APC基因启动子区甲基化及mRNA表达检测显示文摘目的探讨乳腺癌发生模型MCF10中抑癌基因APC启动子区甲基化状态及其对mRNA表达的影响。方法应用甲基化特异性聚合酶链反应(MSP)及双亚硫酸钠基因测序技术检测MCF10模型的乳腺增生细胞系MCF10A、癌前细胞系MCF10AT、导管内癌细胞系MCF10DC IS.com、浸润癌细胞系MCF10CA1 a、MCF10CA1d、MCF10CA1h及经典乳腺癌细胞系MCF-7和正常乳腺组织中APC基因启动子1A甲基化状态,然后用逆转录聚合酶链反应(RT-PCR)和实时PCR技术检测上述样品的mRNA表达水平。结果在MCF10模型的增生细胞系、癌前细胞系、导管内癌细胞系、浸润癌细胞系中,APC基因启动子1A处于低甲基化状态;与正常乳腺组织相比,各细胞系APC基因mRNA表达无明显减少,MCF10AT、MCF10CA1d、MCF10CA1h、MCF10DC IS.com的mRNA表达分别减少0.27、0.96、1.78、2.70、2.03倍,MCF10A和MCF-7分别增加0.02和0.33倍)。结论MCF10模型中乳腺癌的发生发展过程与APC基因启动子区异常甲基化无关。 | 杨举伦 David Klinkebiel Michael J Boland Lin Tang Judith K Christman | 2006 | 中华病理学杂志2006，35，1： | 7 |
| 2 | 乳腺癌发生模型MCF10各阶段细胞系中TIMP3基因启动子区甲基化分析显示文摘目的探讨抑癌基因TIMP3失活与乳腺癌发生和进展的关系。方法用甲基化特异性PCR技术和亚硫酸盐测序技术检测乳腺癌发生模型MCF10的增生细胞系MCF10A、癌前细胞系MCF10AT、导管内癌细胞系MCF10DCIS.com、浸润癌细胞系MCF10CA1a和转移癌细胞系MCF10CA1d、MCF10CA1h中TIMP3启动子区甲基化状态。结果甲基化特异性PCR分析显示,在上述各细胞系中,TIMP3启动子区均呈高度甲基化状态。亚硫酸盐测序显示,在上述各细胞系中,测序区内的68个CG位点几乎全部发生了甲基化,且甲基化累及了绝大部分等位基因。结论TIMP3基因启动子区甲基化在乳腺癌的发生和进展中起重要作用,可能成为早期诊断乳腺癌和判断乳腺癌预后的分子生物学标记。 | 杨举伦 David Klinkebiel Michael J Boland Lin Tang Judith K Christman | 2006 | 临床与实验病理学杂志2006，22，1： | 7 |
| 3 | 乳腺癌发生过程中NOEY2基因启动子区甲基化及mRNA表达显示文摘目的探讨乳腺癌发生过程中抑癌基因NOEY2启动子区甲基化状态及其对mRNA表达的影响。方法应用甲基化特异性PCR及双亚硫酸钠基因测序技术检测MCF10模型中乳腺增生细胞系MCF10A、癌前细胞系MCF10AT、导管内癌细胞系MCF10DC IS.com、浸润癌细胞系MCF10CA1 a、MCF10CA1d、MCF10CA1h及正常乳腺组织中NOEY2基因启动子区CpG岛I甲基化状态,然后用RT-PCR和实时PCR技术检测上述样品的mRNA表达水平。结果MCF10模型的增生细胞系、癌前细胞系、导管内癌细胞系、浸润癌细胞系均发生该基因启动子区CpG岛I高度甲基化;与正常乳腺组织相比,上述细胞系mRNA表达显著减少。结论NOEY2基因启动子区高度甲基化及相应的mRNA表达减少是乳腺癌发生过程中的早期事件,与乳腺癌发生有关,可能成为早期诊断乳腺癌的潜在分子生物学标记。 | 杨举伦 David Klinkebiel Michael J Boland Lin Tang Judith K Christman | 2005 | 临床与实验病理学杂志2005，21，5： | 6 |
| 4 | AJCN:过敏症来袭怎么办?新型益生菌组合疗法显神效显示文摘当进入过敏季节我们可能并不太会拿出手帕或者打喷嚏来预防过敏。日前,一项刊登在国际杂志The American Journal of Clinical Nutrition上的研究报告中。来自佛罗里达大学的研究人员通过研究发现。一种益生菌组合或许能够帮助减轻花粉症的症状。 | Jennifer C Dennis-Wall Tyler Culpepper Carmelo Nieves Jr. Cassie C Rowe Alyssa M Burns Carley T Rusch Ashton Federico Maria Ukhanova Sheldon Waugh Volker Mai Mary C Christman Bobbi Langkamp-Henken | 2017 | 现代生物医学进展2017，17，18： | 3 |
| 5 | 乳腺癌发生模型MCF10抑癌基因NOEY2启动子区甲基化及mRNA表达显示文摘 | 杨举伦 David Klinkebiel Michael J Boland Lin Tang Judith K Christman | 2005 | 中华病理学杂志2005，34，3： | 3 |
| 6 | Probiotic Medilac-S^(█) for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis显示文摘AIM To assess the effects of probiotic Medilac-S~ as adjunctive therapy for the induction of remission of ulcerative colitis(UC) in a Chinese population through a systematic review and meta-analysis. METHODS A systematic literature search was conducted to find randomized, controlled trials in a Chinese population with at least two study arms-a control arm which receives a conventional, oral aminosalicylate drug, and a treatment arm, which administers the same conventional drug in conjunction with the probiotic Medilac-S~ per os. Both English and Chinese databases were searched, including Pub Med, EMBASE, Google Scholar, Chinese National Knowledge Infrastructure, Wanfang Data, and VIP Search, and study data was extracted onto standardized abstraction sheets. Meta-analyses were conducted for primary and secondary outcomes of interest using a fixed or random effects model. The primary outcome was the induction of clinical remission and the secondary outcomes included changes in Sutherland index, endoscopic and histological scores, proportion of reported clinical symptoms and adverse events(AEs). For outcomes with sufficient data, the type of conventional drug therapy was also assessed to determine if the effects of combination therapy with Medilac-S~ was influenced by drug type. All tests were conducted using a type Ⅰ error rate of 0.05 and all confidence intervals(CI) were based on a 95% confidence level. Review protocol was uploaded to PROSPERO(CRD42018085658 upon completion).RESULTS Fifty-three clinical trials with a total of 3984 participants were identified and included in the review. Medilac-S~ adjunctive therapy significantly improved induction of clinical remission(RR = 1.21; 95%CI: 1.18-1.24; P < 0.0001) with the estimated likelihood of effective treatment, on average, 21% higher for those consuming the probiotic. Sutherland index scores showed the control mean was on average 3.10(CI: 2.41-3.78; P = 0.0428) units greater than the treatment mean, thereby demonstrating significant improvement in participants taking the probiotic. Similarly, a significant difference was seen between the overall reduction of endoscopic and histological scores of control and treatment arm participants, with score decreases in the control groups 0.71(CI: 0.3537-1.0742) and 1.1(CI: 0.9189-1.2300) units smaller than treatment group score decreases. The proportion of participants reporting clinical symptoms,(abdominal pain, tenesmus, blood and mucous in stool, and diarrhea) was significantly reduced after combination therapy with Medilac-S~(P < 0.0001) and estimated to be on average 44%(RR = 0.44, CI: 0.32-0.59), 53%(RR = 0.53, CI: 0.38-74), 40%(RR = 0.40, CI: 0.28-0.58) and 47%(RR = 0.47 CI: 0.36-0.42) respectively, of the proportion of individuals reporting the aforementioned symptoms after conventional therapy alone. The risk of AEs was also significantly reduced with adjunctive Medilac-S~ therapy. The proportion of individuals in the treatment groups reporting AEs was an estimated 72% of the proportion of individuals in the control groups reporting AEs(RR = 0.72, CI: 0.55-0.94, P = 0.0175). Upon comparing effect means for different drug types in conjunction with Medilac-S~, evidence of significant variability(P < 0.0001) was observed, and sulfasalazine was found to be the most effective drug in both primary and secondary outcomes. CONCLUSION Evidence suggests Medilac-S~ adjunctive therapy should be considered standard care for UC in a Chinese population because it aids in the induction of clinical remission, improves symptoms of the gastrointestinal tract and reduces risk of AEs. | Ghania Sohail Xiaoyu Xu Mary C Christman Thomas A Tompkins | 2018 | World Journal of Clinical Cases2018，6，15： | 3 |
| 7 | Future directions in myoma research显示文摘 | Brahma P K Martel K M Christman G M | 2006 | Obstet Gynecol Clin North Am2006，33，1： | 1 |
| 8 | A sensible approach to the nutritional sup-port of mechanically ventilated critically ill patients显示文摘 | Christman JW | 1993 | Intensive Care Med1993，19，3： | 1 |
| 9 | Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells显示文摘 | Christman JK Mendelsohn N Herzog D | 1983 | Cancer Res1983，43，： | 1 |
| 10 | Ultrastructural studies of diffuse axconal injury in human显示文摘 | CHRISTMAN C W GRADY M S WALKER S A | 1994 | J Neurotrauma1994，11，2： | 1 |
| 11 | 5 - Azacytidine and 5 - aza - 2' - deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy 显示文摘 | Christman JK | 2002 | Oncogene2002，21，35： | 1 |
| 12 | Pathogen- host interactions in Pseudomonas aeruginosa pneumonia显示文摘 | Sadikot R T Blackwell T S Christman J W | 2005 | Am J RespirCrit Care Med2005，171，11： | 1 |
| 13 | The pathobiology of traumatical y induced axonal injury in animals and humans:a review of current thoughts显示文摘 | Povlishock JT Christman CW | | 0，，04： | 1 |
| 14 | The role of nuclear factor-kappa B in cytokine gene regulation显示文摘 | BLACKWELL T S CHRISTMAN J W | 1997 | Am J Respir Cell Mol Biol1997，7，1： | 1 |
| 15 | Influence of norethynodrel with mestranol on intraocular pressure in glaucoma显示文摘 | Meyer EJ Leibowitz H Christman EH | 1996 | Arch Ophthalmol1996，75，2： | 1 |
| 16 | Ultrastructural studies of diffuse axonal injury in humans 显示文摘 | Christman C W Grady M S Walker S A | 1994 | J Neurotrauma1994，11，2： | 1 |
| 17 | The role of nuclear factor-κB in cytokine gene regu-lation显示文摘 | Blackwell T S Christman J W | | 0，，： | 1 |
| 18 | The role of nuclear factor-kappa B in pulmonary diseases显示文摘 | Christman JW Sadikot RT Blackwell TS | 2000 | Chest2000，117，5： | 1 |
| 19 | The role of nuclear factor-κB in cyto-kinegene regulation显示文摘 | Blackwell T S Christman J W | 1997 | Am J Respir Cell Mol Biol1997，17，1： | 1 |
| 20 | 5 - Azacytidine and 5 - aza - 2'- deoxycytidine as inhibitors of DNA methylation : mechanistic studies and their im- plications for cancer therapy显示文摘 | Christman JK | 2002 | Oncogene2002，21，35： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员